BJJ:TKA术后非感染性伤口并发症影响临床疗效

2014-06-04 佚名 丁香园

现较多研究表明关节置换术后伤口并发症如渗出、不愈合、裂开等与术后关节深部感染发生有显著相关性,深部感染影响长期临床疗效同样较多文献报道,而非感染性伤口并发症是否影响术后疗效却鲜有报道。 为了明确需要再次返院处置的术后非感染性伤口并发症是否对术后关节置换疗效有影响,美国Adelani教授回顾性分析全膝置换后发生非感染性伤口并发症患者术后2年临床疗效,结果发表在近期BJJ上。【原文下载】

现较多研究表明关节置换术后伤口并发症如渗出、不愈合、裂开等与术后关节深部感染发生有显著相关性,深部感染影响长期临床疗效同样较多文献报道,而非感染性伤口并发症是否影响术后疗效却鲜有报道。

为了明确需要再次返院处置的术后非感染性伤口并发症是否对术后关节置换疗效有影响,美国Adelani教授回顾性分析全膝置换后发生非感染性伤口并发症患者术后2年临床疗效,结果发表在近期BJJ上。【原文下载】

2005年1月-2010年1月共2221例首次TKA,121例(105例患者)术后90天内因各种原因需再次返院,返院率5.4%。54例因内科并发症返院;67例因手术并发症返院,其中22例ROM受限、17非感染性伤口并发症、12例深部感染、12例凝血障碍、4例VTE。



纳入标准:因非感染性伤口并发症返院患者(伤口渗出、裂开、不愈合、血肿形成、关节积血),至少随访1年,再次返院时关节穿刺、细菌培养阴性排除感染可能。最终15例(伤口渗出4例、裂开5例、不愈合、血肿形成5例、关节积血1例)纳入研究,11例男性、4例女性,平均年龄66岁。

再依据以上15例患者术前基本情况,匹配30例TKA术后90天内未因任何手术并发症返院者为对照组。术前、末次随访评价两组患者ROM、膝关节疼痛评分、膝关节功能评分(KSFS)。

所有患者伤口由实习生或助理缝合,关节囊层1号Vicryl间断缝合,皮下层2-0 Monocryl间断缝合,订书机缝合表皮。常规负压引流,术后1天拔除,术后2周拆线。

15例患者平均返院住院天数5.6天(2-16天)。11例需再次手术干预,其中6例浅层清创术未打开关节腔,2例保留聚乙烯衬垫行关节内清创术,2例术中彻底清洗关节后侧更换衬垫行关节内清创术,1例行腓肠肌皮瓣移植关闭伤口;4例静滴抗生素+局部换药。1例患者返院期间二次清创处置;2例患者二次返院,其中1例因伤口裂开、1例因贫血。

结果:

1、伤口并发症组出现1例因关节活动受限需麻醉下行手法松解,对照组无。

2、末次随访伤口并发症组关节轻度以上疼痛者11例(73%),中度以上疼痛者2例(13%);对照组轻度以上疼痛者10例(33%),中度以上疼痛者无。疼痛方面并发症组明显差于对照组。

3、末次随访平均KSFS伤口并发症组46分明显差于对照组66分。

本次研究中病例数较少,随访年限较短(2年);但作者认为随访年限2年足够因以往研究表明关节置换术后1年关节活动度已稳定;该研究从另一个角度表明不管是否导致术后感染发生,都应该重视术后伤口并发症,告知患者出现伤口并发症时临床疗效将会受影响,当然更大样本研究仍需。

原始出处:

Adelani MA1, Johnson SR, Keeney JA, Nunley RM, Barrack RL.Clinical outcomes following re-admission for non-infectious wound complications after primary total knee replacement.Bone Joint J. 2014 May;96-B(5):619-21. doi: 10.1302/0301-620X.96B5.33479.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655330, encodeId=108816553304e, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Feb 06 09:41:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757611, encodeId=3eac1e57611bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Oct 03 03:41:00 CST 2014, time=2014-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907142, encodeId=94d8190e1420c, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Jul 06 05:41:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526982, encodeId=dd3415269822c, content=<a href='/topic/show?id=b0521e501d3' target=_blank style='color:#2F92EE;'>#TKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17501, encryptionId=b0521e501d3, topicName=TKA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f6711785285, createdName=liuhuangbo, createdTime=Fri Jun 06 04:41:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819416, encodeId=25901819416f8, content=<a href='/topic/show?id=802299441f5' target=_blank style='color:#2F92EE;'>#非感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99441, encryptionId=802299441f5, topicName=非感染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sun Sep 07 11:41:00 CST 2014, time=2014-09-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655330, encodeId=108816553304e, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Feb 06 09:41:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757611, encodeId=3eac1e57611bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Oct 03 03:41:00 CST 2014, time=2014-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907142, encodeId=94d8190e1420c, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Jul 06 05:41:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526982, encodeId=dd3415269822c, content=<a href='/topic/show?id=b0521e501d3' target=_blank style='color:#2F92EE;'>#TKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17501, encryptionId=b0521e501d3, topicName=TKA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f6711785285, createdName=liuhuangbo, createdTime=Fri Jun 06 04:41:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819416, encodeId=25901819416f8, content=<a href='/topic/show?id=802299441f5' target=_blank style='color:#2F92EE;'>#非感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99441, encryptionId=802299441f5, topicName=非感染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sun Sep 07 11:41:00 CST 2014, time=2014-09-07, status=1, ipAttribution=)]
    2014-10-03 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655330, encodeId=108816553304e, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Feb 06 09:41:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757611, encodeId=3eac1e57611bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Oct 03 03:41:00 CST 2014, time=2014-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907142, encodeId=94d8190e1420c, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Jul 06 05:41:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526982, encodeId=dd3415269822c, content=<a href='/topic/show?id=b0521e501d3' target=_blank style='color:#2F92EE;'>#TKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17501, encryptionId=b0521e501d3, topicName=TKA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f6711785285, createdName=liuhuangbo, createdTime=Fri Jun 06 04:41:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819416, encodeId=25901819416f8, content=<a href='/topic/show?id=802299441f5' target=_blank style='color:#2F92EE;'>#非感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99441, encryptionId=802299441f5, topicName=非感染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sun Sep 07 11:41:00 CST 2014, time=2014-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655330, encodeId=108816553304e, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Feb 06 09:41:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757611, encodeId=3eac1e57611bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Oct 03 03:41:00 CST 2014, time=2014-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907142, encodeId=94d8190e1420c, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Jul 06 05:41:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526982, encodeId=dd3415269822c, content=<a href='/topic/show?id=b0521e501d3' target=_blank style='color:#2F92EE;'>#TKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17501, encryptionId=b0521e501d3, topicName=TKA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f6711785285, createdName=liuhuangbo, createdTime=Fri Jun 06 04:41:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819416, encodeId=25901819416f8, content=<a href='/topic/show?id=802299441f5' target=_blank style='color:#2F92EE;'>#非感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99441, encryptionId=802299441f5, topicName=非感染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sun Sep 07 11:41:00 CST 2014, time=2014-09-07, status=1, ipAttribution=)]
    2014-06-06 liuhuangbo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655330, encodeId=108816553304e, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Feb 06 09:41:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757611, encodeId=3eac1e57611bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Oct 03 03:41:00 CST 2014, time=2014-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907142, encodeId=94d8190e1420c, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Jul 06 05:41:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526982, encodeId=dd3415269822c, content=<a href='/topic/show?id=b0521e501d3' target=_blank style='color:#2F92EE;'>#TKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17501, encryptionId=b0521e501d3, topicName=TKA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f6711785285, createdName=liuhuangbo, createdTime=Fri Jun 06 04:41:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819416, encodeId=25901819416f8, content=<a href='/topic/show?id=802299441f5' target=_blank style='color:#2F92EE;'>#非感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99441, encryptionId=802299441f5, topicName=非感染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sun Sep 07 11:41:00 CST 2014, time=2014-09-07, status=1, ipAttribution=)]

相关资讯

JOA:非骨水泥型假体一期翻修治疗假体感染

假体周围感染是关节置换术后的最严重并发症,给患者带来极大的痛苦,往往需要进行翻修手术。对于慢性假体周围感染,分期翻修手术是其治疗的金标准,据文献报道分期翻修手术的成功率在80%至95%之间。使用含抗生素的骨水泥一期置换翻修是治疗假体周围感染的另外一种选择,在特定的患者中具有较高的成功率(75%至90%)。 虽然使用不含抗生素的假体进行一期翻修的首次研究得到的临床结果并不满意,但是在某些时候使

CORR:OA患者关节置换术后身体活动水平并无提高

老年骨性关节将导致患者关节疼痛和功能障碍,影响患者的日常及工作活动。全髋、全膝关节置换可以迅速缓解疼痛、改善肢体功能,提高生活质量。但是关节置换术后患者的的身体活动情况在术后能否得到提高却一直没有明确的研究。【原文下载】 针对上述问题,澳大利亚的Paula Harding D医生首次使用GT1M加速器对全髋全膝关节置换患者的身体活动情况进行了一项研究,发现骨性关节炎患者进行关节置换术后患者客

AAOS 2014:他汀类药物或可降低关节置换术后的血栓风险

长期以来,人们对他汀类药物的认识即为降低胆固醇药物,但最近,有研究发现,在非手术健康患者中,该类药物可减低深静脉血栓形成的发生风险。在3月11日的2014 美国骨外科学会(AAOS)年会上,研究者首次汇报了一项新研究,该研究显示,他汀类药物与常规血栓预防治疗联用可显著降低全关节置换(TJR)术后患者深静脉血栓形成(VTE)事件的发生风险,这项研究是相关领域进行的第一项研究。

JBJS:髋膝关节置换术后静脉血栓栓塞性疾病的预防

研究要点:1.选择关节置换术后预防静脉血栓栓塞的措施应该兼顾安全性和有效性,出血无疑会对临床结果产生负面影响。2.最近,美国骨科医师学会(AAOS)和美国胸科医师学会(ACCP)联合制定了关节置换术后预防静脉血栓栓塞的循证指南。3.对于常规的关节置换术后,应该选用哪种药物进行预防以及预防应该持续的时间,AAOS指南制定小组在现有文献的基础上尚无法给出明确的推荐。4.ACCP的指南制定小组推荐至